Key result
Oral salsalate treatment for 3 and 6 months had no effect on brachial artery flow-mediated dilation and nitroglycerin-mediated dilation in patients with type 2 diabetes.
Why the study?
Does oral salsalate treatment improve brachial artery flow-mediated dilation in patients with type 2 diabetes?
Does oral salsalate treatment improve brachial artery flow-mediated dilation in patients with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
This comment discusses findings that salsalate does not improve endothelial function in patients with type 2 diabetes, suggesting inflammation may not directly cause endothelial dysfunction in this population or benefits are masked.
We read with interest the study by Goldfine et al. (1) in the recent issue of Diabetes Care that reported that 3 and 6 months of oral salsalate treatment, as part of the multicenter Targeting Inflammation Using Salsalate in Type 2 Diabetes (TINSAL-T2D) trial, had no effect on brachial artery flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (measurements of endothelium-dependent and -independent dilation, respectively) in patients with type 2 diabetes (T2D). The authors concluded that their findings suggest that 1 ) salsalate does not inhibit vascular inflammation, 2 ) inflammation does not cause endothelial dysfunction in patients with T2D, or 3 ) the potential benefits of salsalate were masked by the unfavorable changes in serum …
No takes yet. Share an insight, caveat, or question.
Pierce et al. (2014) conducted a letter in Type 2 diabetes (T2D). Oral salsalate was evaluated on Brachial artery flow-mediated dilation (FMD) and nitroglycerin-mediated dilation. Oral salsalate treatment for 3 and 6 months had no effect on brachial artery flow-mediated dilation and nitroglycerin-mediated dilation in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: